Clinical Research by Disease

The Department of Radiation Oncology enrolls as many as 80 new patients each year in clinical trials. Faculty members hold leadership positions in the Radiation Therapy Oncology Group (RTOG), which develops and oversees all national radiation oncology trials funded by the National Cancer Institute.

See current clinical trial information below or contact the Clinical Research office at 214-648-5536.


Interstitial radioactive iodine implants for the treatment of pan-invasive pituitary macroadenomas
Phase II trial of hippocampal-avoiding whole brain irradiation with simultaneous integrated boost for treatment of brain metastases

Phase III study of radiation therapy with or without Temozolomide for symptomatic or progressive low-grade gliomas


Phase I study of CyberKnife® partial breast irradiation (PBI) for early stage breast cancer

Phase II study of repeat breast preserving surgery and 3D-conformal partial breast re-irradiation (PBRI) for local recurrence of breast carcinoma
RTOG 1014

Phase III trial of accelerated whole breast Irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early-stage breast cancer
RTOG 1005


Dose escalating study of single fraction stereotactic body radiation therapy (SBRT) for patients with hepatic metastases

Phase III trial evaluating the addition of Trastuzumab to trimodality treatment of Her2-overexpressing esophageal adenocarcinoma
RTOG 1010


Phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by Paclitaxel/Carboplatin in patients with high-risk, early-stage endometrial cancer
GOG 0249

A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus
GOG 0238

A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for optimally debulked, advanced endometrial carcinoma
GOG 0258

Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy
GOG 0724

Head and Neck

Phase II, multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALD518 in the reduction of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy

Phase II multi-center study of concomitant Cetuximab and Cisplatin with re-irradiation using intensity-modulated radiotherapy (IMRT) in patients with recurrent squamous cell carcinoma of the head and neck

Phase I/II study of Nab-paclitaxel, Cisplatin, and Cetuximab with concurrent radiation therapy for local-regionally advanced head-and-neck squamous cell carcinoma

Phase III study of postoperative radiation therapy (IMRT) /- Cetuximab for locally-advanced resected head and neck cancer
RTOG 0920

Randomized Phase II study of adjuvant concurrent radiation and chemotherapy versus radiation alone in resected high-risk malignant salivary gland tumors
RTOG 1008

Lung (Thoracic)

Small Cell Lung Cancer

Phase III comparison of thoracic radiotherapy regimes with Cisplatin and Etoposide in limited small cell lung cancer
CALGB 30610/RTOG 0538

Randomized Phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial Irradiation and consolidative extracranial Irradiation for extensive disease small cell lung cancer (ED-SCLC)
RTOG 0937

Non-Small Cell Lung Cancer

Stage I

Randomized Phase III study of sublobar resection (+/- brachytherapy) versus stereotactic body radiation therapy in high-risk patients with Stage I NSCLC
RTOG 1021

Locally Advanced (Stage III) or Inoperable (Stage I or Stage II)

Seamless Phase I/II study of stereotactic body radiotherapy (SBRT) for early stage, centrally-located non-small cell lung cancer (NSCLC) in medically inoperable patients
RTOG 0813

Randomized Phase II study of preoperative chemoradiotherapy +/- Panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (Stage IIIA, N2+) non-small cell lung cancer
RTOG 839

Phase I study of accelerated hypofractionated image-guided radiation therapy (IGRT) in patients with Stage II-IV non-small cell lung cancer and poor performance status

Metastatic (2 or more sites)

Phase II trial of Erlotinib (Tarceva®) in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)


Investigating the feasibility of using rapid cine-MRI for monitoring moving and deforming tumors

Prostate and Bladder

Phase III trial of short-term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate Cancer patients with a rising PSA After radical prostatectomy
RTOG 0534

Phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer
RTOG 0815

Phase III trial of dose escalated radiation therapy and atandard androgen deprivation therapy (ADT) with a GnRH agonist vs. dose-escalated radiation therapy and enhanced ADT with a GnRH agonist and TAK-700 for men with high-risk prostate cancer
RTOG 1115


Phase II study of stereotactic body radiation therapy and vertebroplasty for localized spine metastasis

Phase II/III study of Image-guided radiosurgery/SBRT for localized spine metastasis
RTOG 0631

For more information, please contact Clinical Research Manager Jean Wu at 214-633-1753 or